These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23168176)

  • 1. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
    Stamelos VA; Robinson E; Redman CW; Richardson A
    Gynecol Oncol; 2013 Feb; 128(2):377-82. PubMed ID: 23168176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of statins as a treatment for ovarian cancer.
    Robinson E; Nandi M; Wilkinson LL; Arrowsmith DM; Curtis AD; Richardson A
    Gynecol Oncol; 2013 May; 129(2):417-24. PubMed ID: 23402903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models.
    Wong M; Tan N; Zha J; Peale FV; Yue P; Fairbrother WJ; Belmont LD
    Mol Cancer Ther; 2012 Apr; 11(4):1026-35. PubMed ID: 22302098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
    Smith JA; Ngo H; Martin MC; Wolf JK
    Gynecol Oncol; 2005 Jul; 98(1):141-5. PubMed ID: 15963813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models.
    Tan N; Malek M; Zha J; Yue P; Kassees R; Berry L; Fairbrother WJ; Sampath D; Belmont LD
    Clin Cancer Res; 2011 Mar; 17(6):1394-404. PubMed ID: 21220478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
    Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmented growth inhibition of B16-BL6 melanoma by combined treatment with a selective matrix metalloproteinase inhibitor, MMI-166, and cytotoxic agents.
    Hojo K; Maki H; Sawada TY; Maekawa R; Yoshioka T
    Anticancer Res; 2002; 22(6A):3253-9. PubMed ID: 12530072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas.
    Jain HV; Meyer-Hermann M
    Cancer Res; 2011 Feb; 71(3):705-15. PubMed ID: 21169413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.
    Marchion DC; Bicaku E; Xiong Y; Bou Zgheib N; Al Sawah E; Stickles XB; Judson PL; Lopez AS; Cubitt CL; Gonzalez-Bosquet J; Wenham RM; Apte SM; Berglund A; Lancaster JM
    Oncol Rep; 2013 May; 29(5):2011-8. PubMed ID: 23467907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
    Modesitt SC; Parsons SJ
    Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors.
    Vlahovic G; Karantza V; Wang D; Cosgrove D; Rudersdorf N; Yang J; Xiong H; Busman T; Mabry M
    Invest New Drugs; 2014 Oct; 32(5):976-84. PubMed ID: 24894650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum compounds in the treatment of advanced breast cancer.
    Martín M
    Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of antitumor activities of carboplatin and camptothecin by interleukin-1 alpha against human ovarian carcinoma in vivo.
    Wang Z; Benchekroun MN; Sinha BK
    Anticancer Res; 1994; 14(5A):1723-6. PubMed ID: 7847805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel plus carboplatin in the treatment of ovarian cancer.
    Ozols RF
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):84-9. PubMed ID: 10190787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients.
    Flick MB; O'Malley D; Rutherford T; Rodov S; Kamsteeg M; Hao XY; Schwartz P; Kacinski BM; Mor G
    J Soc Gynecol Investig; 2004 May; 11(4):252-9. PubMed ID: 15120700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel and carboplatin for advanced breast cancer.
    Perez EA; Hartmann LC
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):41-5. PubMed ID: 8893899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro responses of ovarian cancers to platinums and taxanes.
    Kornblith P; Wells A; Gabrin MJ; Piwowar J; Chattopadhyay A; George LD; Ochs RL; Burholt D
    Anticancer Res; 2003; 23(1B):543-8. PubMed ID: 12680143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
    Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.